XOMA Declares Quarterly Preferred Stock Dividends
June 21 2021 - 6:30AM
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today
announced its Board of Directors has authorized the following cash
dividends to holders of XOMA’s Series A and Series B Cumulative
Preferred Stock:
Holders of the 8.625% Series A Cumulative Perpetual Preferred
Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.539
per share.
Holders of depositary shares, each representing 1/1000 of XOMA’s
8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq:
XOMAO), shall receive a cash dividend equal to $0.55833 per
depositary share.
The preferred dividends will be paid on or about July 15, 2021,
to respective holders of record at the close of business on July 2,
2021.
About XOMA CorporationXOMA is a biotechnology
royalty aggregator playing a unique role in helping biotech
companies achieve their goal of improving human health. XOMA
acquires the potential future economics associated with
pre-commercial therapeutic candidates that have been licensed to
pharmaceutical or biotechnology companies. When XOMA acquires
the future economics, the seller receives non-dilutive,
non-recourse funding they can use to advance their internal drug
candidate(s) or for general corporate purposes. The Company
has an extensive and growing portfolio with more than 70 assets
(asset defined as the right to receive potential future economics
associated with the advancement of an underlying therapeutic
candidate). For more information about the Company and its
portfolio, please visit www.xoma.com.
Safe Harbor Statement / Explanatory NotesThis
release contains “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. “Forward-looking statements” describe future
expectations, plans, results, or strategies and are generally
preceded by words such as “anticipates”, “expect”, “may”, “plan”,
or “will”. Forward-looking statements include, without
limitation, projections, predictions, expectations, or beliefs
about future events or results and are not statements of historical
fact, including statements regarding the Company’s expectations
regarding payments of dividends in the future. You are
cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events, or
results to differ materially from those projected in the
forward-looking statements, including the availability of, and
participation in, financing opportunities. These and other
risks are identified in our filings with the Commission, including
without limitation our Annual Report on Form 10-K for the year
ended December 31, 2020, our Quarterly Report on Form 10-Q for the
three months ended March 31, 2021, and in other filings
subsequently made by the Company with the Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management’s assumptions and estimates as of such date. We do
not undertake any obligation to publicly update any forward-looking
statements, whether as a result of the receipt of new information,
the occurrence of future events or otherwise.
EXPLANATORY NOTE: Any references to “portfolio” in this press
release refer strictly to milestone and/or royalty rights
associated with a basket of drug products in development. Any
references to “assets” in this press release refer strictly to
milestone and/or royalty rights associated with individual drug
products in development. References to royalties or royalty
rates strictly refer to future potential payment streams regardless
of whether or not they are technically defined as royalties in the
underlying contractual agreement; further, any rates referenced
herein are subject to potential future contractual adjustments.
As of the date of this press release, all assets in XOMA’s
milestone and royalty portfolio are investigational
compounds. Efficacy and safety have not been
established. There is no guarantee that any of these assets
will become commercially available.
Investor contact: |
|
|
Gitanjali JainSolebury Trout+1
646-378-2949gogawa@soleburytrout.com |
|
Juliane SnowdenXOMA+1 646-438-9754juliane.snowden@xoma.com |
|
|
|
Media contact: |
|
|
Kathy VincentKV Consulting & Management+1
310-403-8951kathy@kathyvincent.com |
|
|
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2024 to May 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From May 2023 to May 2024